Table 1.
Baseline demographics and characteristics
| Baseline characteristics | All patients (N = 27) |
|---|---|
| Age, median (range), y | 56.0 (34-74) |
| Males | 16 (59) |
| Time since PV diagnosis, median (range), y | 6.3 (0.6-27.5) |
| Prior thrombosis | 2 (7) |
| Baseline TSS, median (IQR)* | 31 (15-40) |
| Baseline score of GHS/QoL and EORTC QLQ-C30, median (IQR)† | 66.7 (50.0-66.7) |
| Reason for HU discontinuation | |
| Intolerance | 24 (89) |
| Resistance | 5 (19) |
| Intolerance and resistance | 2 (7) |
| Prior cytoreductive therapies,‡ n (%) | |
| Ruxolitinib | 7 (26) |
| IFN-α | 5 (19) |
| Ruxolitinib and IFN-α | 1 (4) |
| None | 14 (52) |
| Median JAK2 V617F VAF (range), % | 65.7 (7-96) |
| Cytogenetic abnormalities | 2 (7) |
| Splenomegaly§ | 21 (78) |
| Spleen volume in patients with splenomegaly, median (range), cm3 | 800.0 (513.0-2602.4) |
| Baseline hematocrit, median (range), % | 43 (40-50) |
| Baseline WBC count, median (range), ×109/L | 13.7 (5-44) |
| Baseline platelet count, median (range), ×109/L | 576.0 (176-2314) |
Unless otherwise noted, data are n (%).
GHS, Global Health Status; IQR, interquartile range; WBC, white blood cell.
*
Data available for n = 25 patients.
†
The overall GHS/QoL scale was calculated from a combination of the GHS and QoL items; therefore, the baseline score reported here is composed of the score of both items for N = 27.
‡
Excluding HU.
§
Spleen volume > 450 cm3, as determined by imaging.